{"id":"NCT03692312","sponsor":"AMO Pharma Limited","briefTitle":"Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy","officialTitle":"A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-03-03","primaryCompletion":"2023-04-04","completion":"2023-04-04","firstPosted":"2018-10-02","resultsPosted":"2025-09-11","lastUpdate":"2025-09-11"},"enrollment":56,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Myotonic Dystrophy"],"interventions":[{"type":"DRUG","name":"Tideglusib","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tideglusib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of patients (aged 6 to 16 years) diagnosed with Congenital Myotonic Dystrophy (Congenital DM1).","primaryOutcome":{"measure":"Change in Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS)","timeFrame":"Baseline and week 20","effectByArm":[{"arm":"Tideglusib","deltaMin":-1.65,"sd":0.62},{"arm":"Placebo","deltaMin":-3.4,"sd":0.618}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0514"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States","Australia","Canada","New Zealand","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":28},"commonTop":["Diarrhea","Nasopharyngytitis","Upper respiratory tract infection","Vomiting","Cough"]}}